Johnson & Johnson Skips Obesity Drugs to Focus on Cancer, Buys Halda for $3.05B
JNJ•Johnson & Johnson will avoid the GLP-1 obesity drug market and instead focus R&D on oncology and neuroscience to drive growth. J&J aims to be the top cancer company by 2030 after its $3.05 billion Halda Therapeutics acquisition and delivered a 47% total shareholder return.
1. Strategy Shift Away from Obesity Drugs
Johnson & Johnson CEO Joaquin Duato announced that the company will not develop or commercialize GLP-1 obesity drugs, opting instead to concentrate R&D and capital on oncology and neuroscience pipelines where it sees greater impact potential.
2. Cancer Leadership and Halda Acquisition
J&J has set a goal of becoming the world’s leading cancer company by 2030, building on its market share in multiple myeloma and lung cancer treatments. The company bolstered its oncology portfolio with a $3.05 billion cash acquisition of Halda Therapeutics in 2025 and delivered a 47% total shareholder return last year.
3. Neuroscience Focus and AI Investment
Duato highlighted dementia as a critical healthcare challenge and confirmed ongoing investments in neurodegenerative disease research despite past setbacks. He also emphasized the role of artificial intelligence in accelerating drug discovery and enhancing its medical devices, particularly robotic surgery systems.
